FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2613020156> ?p ?o ?g. }

• W2613020156 endingPage "1216" @default.
• W2613020156 startingPage "1208" @default.
• W2613020156 abstract "Objective To evaluate factors predicting efficacy, retention, and tolerability of add-on brivaracetam (BRV) in clinical practice. Methods A multicenter, retrospective cohort study recruiting all patients who started BRV between February and November 2016 with observation time between 3 and 12 months. Results Of a total of 262 patients (mean age 40, range 5–81 years, 129 male) treated with BRV, 227 (87%) were diagnosed to have focal, 19 (7%) idiopathic generalized and 8 (3%) symptomatic generalized epilepsy, whereas 8 (3%) were unclassified. The length of exposure to BRV ranged from 1 day to 12 months, with a median retention time of 6.1 months, resulting in a total exposure time to BRV of 1,504 months. The retention rate was 79.4% at 3 months and 75.8% at 6 months. Efficacy at 3 months was 41.2% (50% responder rate) with 14.9% seizure-free for 3 months and, at 6 months, 40.5% with 15.3% seizure-free. Treatment-emergent adverse events were observed in 37.8% of the patients, with the most common being somnolence, dizziness, and behavioral adverse events (BAEs). BAE that presented under previous levetiracetam (LEV) treatment improved upon switch to BRV in 57.1% (20/35) and LEV-induced somnolence improved in 70.8% (17/24). Patients with BAE on LEV were more likely to develop BAE on BRV (odds ratio [OR] 3.48, 95% confidence interval [CI] 1.53–7.95). Significance BRV in broad clinical postmarketing use is a well-tolerated anticonvulsant drug with 50% responder rates, similar to those observed in the regulatory trials, even though 90% of the patients included had previously been exposed to LEV. An immediate switch from LEV to BRV at a ratio of 10:1 to 15:1 is feasible. The only independent significant predictor of efficacy was the start of BRV in patients not currently taking LEV. The occurrence of BAE during previous LEV exposure predicted poor psychobehavioral tolerability of BRV treatment. A switch to BRV can be considered in patients with LEV-induced BAE." @default.
• W2613020156 created "2017-05-19" @default.
• W2613020156 creator A5001857256 @default.
• W2613020156 creator A5005472168 @default.
• W2613020156 creator A5012495517 @default.
• W2613020156 creator A5018035642 @default.
• W2613020156 creator A5020938660 @default.
• W2613020156 creator A5026030959 @default.
• W2613020156 creator A5028930979 @default.
• W2613020156 creator A5045975331 @default.
• W2613020156 creator A5047731378 @default.
• W2613020156 creator A5053538795 @default.
• W2613020156 creator A5054897395 @default.
• W2613020156 creator A5054992600 @default.
• W2613020156 creator A5063015953 @default.
• W2613020156 creator A5081693588 @default.
• W2613020156 creator A5090283124 @default.
• W2613020156 date "2017-05-08" @default.
• W2613020156 modified "2023-10-18" @default.
• W2613020156 title "Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany" @default.
• W2613020156 cites W1530769330 @default.
• W2613020156 cites W1576738253 @default.
• W2613020156 cites W1582497413 @default.
• W2613020156 cites W1916788136 @default.
• W2613020156 cites W1943229448 @default.
• W2613020156 cites W1970318744 @default.
• W2613020156 cites W1974809694 @default.
• W2613020156 cites W1978437325 @default.
• W2613020156 cites W1981401201 @default.
• W2613020156 cites W1992028227 @default.
• W2613020156 cites W1994030717 @default.
• W2613020156 cites W1996493949 @default.
• W2613020156 cites W2000445173 @default.
• W2613020156 cites W2020074777 @default.
• W2613020156 cites W2032960068 @default.
• W2613020156 cites W2051013481 @default.
• W2613020156 cites W2053236663 @default.
• W2613020156 cites W2055878330 @default.
• W2613020156 cites W2078803320 @default.
• W2613020156 cites W2091074713 @default.
• W2613020156 cites W2091661674 @default.
• W2613020156 cites W2099690974 @default.
• W2613020156 cites W2105359051 @default.
• W2613020156 cites W2119181594 @default.
• W2613020156 cites W2140372289 @default.
• W2613020156 cites W2160043884 @default.
• W2613020156 cites W2272342604 @default.
• W2613020156 cites W2409829112 @default.
• W2613020156 cites W2472978162 @default.
• W2613020156 cites W2562398824 @default.
• W2613020156 cites W2567656920 @default.
• W2613020156 cites W2578414214 @default.
• W2613020156 cites W2596267717 @default.
• W2613020156 cites W2607319988 @default.
• W2613020156 cites W3022423927 @default.
• W2613020156 cites W4236069402 @default.
• W2613020156 cites W4376848378 @default.
• W2613020156 doi "https://doi.org/10.1111/epi.13768" @default.
• W2613020156 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28480518" @default.
• W2613020156 hasPublicationYear "2017" @default.
• W2613020156 type Work @default.
• W2613020156 sameAs 2613020156 @default.
• W2613020156 citedByCount "91" @default.
• W2613020156 countsByYear W26130201562017 @default.
• W2613020156 countsByYear W26130201562018 @default.
• W2613020156 countsByYear W26130201562019 @default.
• W2613020156 countsByYear W26130201562020 @default.
• W2613020156 countsByYear W26130201562021 @default.
• W2613020156 countsByYear W26130201562022 @default.
• W2613020156 countsByYear W26130201562023 @default.
• W2613020156 crossrefType "journal-article" @default.
• W2613020156 hasAuthorship W2613020156A5001857256 @default.
• W2613020156 hasAuthorship W2613020156A5005472168 @default.
• W2613020156 hasAuthorship W2613020156A5012495517 @default.
• W2613020156 hasAuthorship W2613020156A5018035642 @default.
• W2613020156 hasAuthorship W2613020156A5020938660 @default.
• W2613020156 hasAuthorship W2613020156A5026030959 @default.
• W2613020156 hasAuthorship W2613020156A5028930979 @default.
• W2613020156 hasAuthorship W2613020156A5045975331 @default.
• W2613020156 hasAuthorship W2613020156A5047731378 @default.
• W2613020156 hasAuthorship W2613020156A5053538795 @default.
• W2613020156 hasAuthorship W2613020156A5054897395 @default.
• W2613020156 hasAuthorship W2613020156A5054992600 @default.
• W2613020156 hasAuthorship W2613020156A5063015953 @default.
• W2613020156 hasAuthorship W2613020156A5081693588 @default.
• W2613020156 hasAuthorship W2613020156A5090283124 @default.
• W2613020156 hasBestOaLocation W26130201561 @default.
• W2613020156 hasConcept C118552586 @default.
• W2613020156 hasConcept C126322002 @default.
• W2613020156 hasConcept C167135981 @default.
• W2613020156 hasConcept C187212893 @default.
• W2613020156 hasConcept C197934379 @default.
• W2613020156 hasConcept C2777332695 @default.
• W2613020156 hasConcept C2778186239 @default.
• W2613020156 hasConcept C2778375690 @default.
• W2613020156 hasConcept C2779034229 @default.
• W2613020156 hasConcept C42219234 @default.
• W2613020156 hasConcept C44249647 @default.

• next